+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment



Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment



Progress in Clinical and Biological Research 391: 325-336




(PDF emailed within 1 workday: $29.90)

Accession: 046973181

Download citation: RISBibTeXText

PMID: 8532725


Related references

Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 20(53): 7812-7816, 2001

Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Toxicology. 102(1-2): 223-237, 1995

Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Research 62(20): 5685-5688, 2002

Activated oncogenes in B6C3F1 mouse liver tumors: implications for risk assessment. Science 237(4820): 1309-1316, 1987

Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacology & Therapeutics 71(1-2): 153-191, 1996

Phenotypic variation in inducibility by phenobarbital pb of a hepatic cytochrome p 450iib isoenzyme activity among c3h x vy f 1 hybrid mice correlation with a predictive biomarker for pb promotion of liver tumors. Proceedings of the American Association for Cancer Research Annual Meeting 30: 216, 1989

Failure to discriminate initiation from promotion of liver tumors in a long-term study with the phenobarbital-type inducer alpha-hexachlorocyclohexane and the role of sustained stimulation of hepatic growth and monooxygenases. Cancer Research 41(10): 4140-4146, 1981

The non-genotoxic tumor promoter phenobarbital modifies the mutational spectrum of mouse liver tumors. Naunyn-Schmiedeberg's Archives of Pharmacology 363(4 Supplement): R156, 2001

Mechanisms of dioxin tumor promotion implications for risk assessment. Chemosphere 25(1-2): 177-180, 1992

Induction of hepatic CYP2B by phenobarbital in spontaneous hepatic tumors or in tumors arising in phenobarbital-treated mice. Proceedings of the American Association for Cancer Research Annual Meeting 34(0): 182, 1993

Induction of epoxide hydrolase and specific forms of cytochrome p 450 and its association with liver tumor promotion species comparison employing phenobarbital rat mouse hamster patas monkey and effects of diverse compounds in the rat. Proceedings of the American Association for Cancer Research Annual Meeting 29: 160, 1988

Positive selection for beta-catenin-mutated and negative selection for Ha-ras-mutated liver tumors in mice during tumor promotion by phenobarbital. Journal of Cancer Research & Clinical Oncology 127(Supplement 1): S33, 2001

Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis 32(1): 52-57, 2011

Liver tumor promotion by ethanol wine or phenobarbital in the rat. Human & Experimental Toxicology 10(1): 69-70, 1991

Dose-response relationship of phenobarbital promotion of diethylnitrosamine initiated tumors in rat liver. Cancer Letters 32(3): 305-311, 1986